| Date | Partners | Compound / Disease area / Development phase | Type of agreement | Nature / Financial terms |
|---|---|---|---|---|
| 2006-02-10 | MAT BioPharma (France) Institut de Recherche Pierre Fabre (France) |
monoclonal antibodies / cancer | R&D |
See details |
| 2006-02-08 | NPS Pharmaceuticals (USA) AstraZeneca (UK) |
drugs targeting metabotropic glutamate receptors / CNS diseases, gastro-intestinal pathologies | R&D commercialization/ distribution |
See details |
| 2006-02-08 | G2Therapies (Australia) Novo Nordisk (Denmark) |
anti-inflammatories based on anti-C5a receptor antibodies / rheumatoid arthritis and other auto-immune diseases | R&D manufacturing commercialization/ distribution |
See details |
| 2006-02-07 | Hybrigenics (France) The Universities of Leuven and Ghent (both Belgium) |
inecalcitol in all its therapeutic indications / Two development axes for this vitamin D analogue: (i) oncology and notably hormone therapy- refractory prostate cancer, (ii) psoriasis and hyperparathyroidism, in collaboration with Theramex. | licensing |
See details |
| 2006-01-27 | Biomira (Canada) Merck KGaA (Germany) |
Stimuvax (liposomal vaccine BLP25) / non-small-cell lung cancer | commercialization/ distribution development |
See details |
| 2006-01-23 | Biovitrum (Sweden) Syntonix (USA) |
recombinant factor IX / haemophilia B | commercialization/ distribution development |
See details |
| 2006-01-18 | Evotec (Germany) Boehringer Ingelheim (Germany) |
therapeutic compounds acting on G-protein-coupled receptors / CNS, inflammation, cardiometabolic and respiratory diseases, oncology | R&D other |
See details |
| 2006-01-16 | BioFocus DPI/Galapagos (Belgium) Boehringer Ingelheim (Germany) |
drug targets / autoimmune diseases | R&D |
See details |
| 2006-01-15 | Nuvelo (USA) Bayer (Germany) |
alfimeprase (an antithrombotic) / acute peripheral arterial occlusion, stroke | commercialization/ distribution development |
See details |
| 2006-01-09 | CancerVax (USA) Micromet (Germany) |
/ oncology, autoimmune and inflammatory diseases | other |
See details |
| 2006-01-01 | Biovitrum (Sweden) Symphogen (Denmark) |
Sym001 (Symphogen's combination of 25 recombinant anti-rhesus D antibodies) / idiopathic thrombocytopenic purpura and neonatal haemolytic disease | commercialization/ distribution development |
See details |
